{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:10:54Z","timestamp":1793459454200,"version":"4.5.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"crossref","award":["Y-SYBLD2022MS-0055"],"award-info":[{"award-number":["Y-SYBLD2022MS-0055"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81974005"],"award-info":[{"award-number":["No. 81974005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["No. 2025AFD777"],"award-info":[{"award-number":["No. 2025AFD777"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01754-4","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T23:30:56Z","timestamp":1750807856000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Angioimmunoblastic T-cell lymphoma: a concise overview encompassing the pathogenetic, pathological, clinical, therapeutical characteristics, and recent advances"],"prefix":"10.1007","volume":"25","author":[{"given":"Yan","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongjuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zetong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"issue":"3","key":"1754_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1182\/blood.2020010387","volume":"138","author":"RH Advani","year":"2021","unstructured":"Advani RH, Skrypets T, Civallero M, Spinner MA, Manni M, Kim WS, et al. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. Blood. 2021;138(3):213\u201320. https:\/\/doi.org\/10.1182\/blood.2020010387.","journal-title":"Blood"},{"issue":"10","key":"1754_CR2","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1038\/s41375-020-0990-y","volume":"34","author":"S Chiba","year":"2020","unstructured":"Chiba S, Sakata-Yanagimoto M. Advances in understanding of angioimmunoblastic T-cell lymphoma. Leukemia. 2020;34(10):2592\u2013606. https:\/\/doi.org\/10.1038\/s41375-020-0990-y.","journal-title":"Leukemia"},{"issue":"11","key":"1754_CR3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1080\/17474086.2019.1652590","volume":"12","author":"A Ohmoto","year":"2019","unstructured":"Ohmoto A, Fuji S. Cyclosporine for angioimmunoblastic T-cell lymphoma: a literature review. Expert Rev Hematol. 2019;12(11):975\u201381. https:\/\/doi.org\/10.1080\/17474086.2019.1652590.","journal-title":"Expert Rev Hematol"},{"issue":"9","key":"1754_CR4","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.it.2014.06.002","volume":"35","author":"N Schmitt","year":"2014","unstructured":"Schmitt N, Bentebibel SE, Ueno H. Phenotype and functions of memory Tfh cells in human blood. Trends Immunol. 2014;35(9):436\u201342. https:\/\/doi.org\/10.1016\/j.it.2014.06.002.","journal-title":"Trends Immunol"},{"issue":"1","key":"1754_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev-immunol-090222-102834","volume":"42","author":"W Song","year":"2024","unstructured":"Song W, Craft J. T follicular helper cell heterogeneity. Annu Rev Immunol. 2024;42(1):127\u201352. https:\/\/doi.org\/10.1146\/annurev-immunol-090222-102834.","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"1754_CR6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.immuni.2014.10.004","volume":"41","author":"S Crotty","year":"2014","unstructured":"Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity. 2014;41(4):529\u201342. https:\/\/doi.org\/10.1016\/j.immuni.2014.10.004.","journal-title":"Immunity"},{"key":"1754_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1177590","author":"L Lage","year":"2023","unstructured":"Lage L, Culler HF, Reichert CO, Da SS, Pereira J. Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1177590.","journal-title":"Front Oncol"},{"issue":"4","key":"1754_CR8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/DAD.0000000000000144","volume":"37","author":"N Botros","year":"2015","unstructured":"Botros N, Cerroni L, Shawwa A, Green PJ, Greer W, Pasternak S, et al. Cutaneous manifestations of angioimmunoblastic T-cell lymphoma: clinical and pathological characteristics. Am J Dermatopathol. 2015;37(4):274\u201383. https:\/\/doi.org\/10.1097\/DAD.0000000000000144.","journal-title":"Am J Dermatopathol"},{"issue":"20","key":"1754_CR9","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569.","journal-title":"Blood"},{"issue":"7","key":"1754_CR10","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo I, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720\u201348. https:\/\/doi.org\/10.1038\/s41375-022-01620-2.","journal-title":"Leukemia"},{"issue":"2","key":"1754_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","volume":"31","author":"M Federico","year":"2013","unstructured":"Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol. 2013;31(2):240\u20136. https:\/\/doi.org\/10.1200\/JCO.2011.37.3647.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1754_CR12","doi-asserted-by":"publisher","first-page":"5480","DOI":"10.3390\/curroncol28060456","volume":"28","author":"SM Mohammed","year":"2021","unstructured":"Mohammed SM, Kotb A, Abdallah G, Muhsen IN, El FR, Aljurf M. Recent advances in diagnosis and therapy of angioimmunoblastic T cell lymphoma. Curr Oncol. 2021;28(6):5480\u201398. https:\/\/doi.org\/10.3390\/curroncol28060456.","journal-title":"Curr Oncol"},{"issue":"25","key":"1754_CR13","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330. https:\/\/doi.org\/10.1200\/JCO.2008.16.4558.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1754_CR14","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1182\/blood-2016-09-692541","volume":"129","author":"MA Lunning","year":"2017","unstructured":"Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood. 2017;129(9):1095\u2013102. https:\/\/doi.org\/10.1182\/blood-2016-09-692541.","journal-title":"Blood"},{"issue":"18","key":"1754_CR15","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1182\/blood.2022015451","volume":"140","author":"M Fujisawa","year":"2022","unstructured":"Fujisawa M, Nguyen TB, Abe Y, Suehara Y, Fukumoto K, Suma S, et al. Clonal germinal center B cells function as a niche for T-cell lymphoma. Blood. 2022;140(18):1937\u201350. https:\/\/doi.org\/10.1182\/blood.2022015451.","journal-title":"Blood"},{"issue":"3","key":"1754_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092585","volume":"9","author":"B Xu","year":"2014","unstructured":"Xu B, Liu P. No survival improvement for patients with angioimmunoblastic T-cell lymphoma over the past two decades: a population-based study of 1207 cases. PLoS ONE. 2014;9(3): e92585. https:\/\/doi.org\/10.1371\/journal.pone.0092585.","journal-title":"PLoS ONE"},{"issue":"9","key":"1754_CR17","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.3324\/haematol.2015.126300","volume":"100","author":"L de Leval","year":"2015","unstructured":"de Leval L, Parrens M, Le Bras F, Jais JP, Fataccioli V, Martin A, et al. Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. Haematologica. 2015;100(9):e361\u20134. https:\/\/doi.org\/10.3324\/haematol.2015.126300.","journal-title":"Haematologica"},{"issue":"2","key":"1754_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ccell.2023.01.003","volume":"41","author":"J Leca","year":"2023","unstructured":"Leca J, Lemonnier F, Meydan C, Foox J, El GS, Mboumba DL, et al. IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment. Cancer Cell. 2023;41(2):323\u201339. https:\/\/doi.org\/10.1016\/j.ccell.2023.01.003.","journal-title":"Cancer Cell"},{"issue":"11","key":"1754_CR19","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1080\/10428194.2023.2235043","volume":"64","author":"E Chang","year":"2023","unstructured":"Chang E, Yang VS, Ong SY, Kang HX, Lim BY, de Mel S, et al. Clinical features and prognostic outcomes of angioimmunoblastic T cell lymphoma in an Asian multicenter study. Leuk Lymphoma. 2023;64(11):1782\u201391. https:\/\/doi.org\/10.1080\/10428194.2023.2235043.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"1754_CR20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.hoc.2016.12.001","volume":"31","author":"A Broccoli","year":"2017","unstructured":"Broccoli A, Zinzani PL. Angioimmunoblastic T-cell lymphoma. Hematol Oncol Clin North Am. 2017;31(2):223\u201338. https:\/\/doi.org\/10.1016\/j.hoc.2016.12.001.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"1754_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10689-018-0099-x","volume":"18","author":"I Donner","year":"2019","unstructured":"Donner I, Katainen R, Kaasinen E, Aavikko M, Sipil\u00e4 LJ, Pukkala E, et al. Candidate susceptibility variants in angioimmunoblastic T-cell lymphoma. Fam Cancer. 2019;18(1):113\u20139. https:\/\/doi.org\/10.1007\/s10689-018-0099-x.","journal-title":"Fam Cancer"},{"issue":"4","key":"1754_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/path.4920","volume":"242","author":"F Lemonnier","year":"2017","unstructured":"Lemonnier F, Mak TW. Angioimmunoblastic T-cell lymphoma: more than a disease of T follicular helper cells. J Pathol. 2017;242(4):387\u201390. https:\/\/doi.org\/10.1002\/path.4920.","journal-title":"J Pathol"},{"issue":"1","key":"1754_CR23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41375-021-01321-2","volume":"36","author":"JC Pritchett","year":"2022","unstructured":"Pritchett JC, Yang ZZ, Kim HJ, Villasboas JC, Tang X, Jalali S, et al. High-dimensional and single-cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL). Leukemia. 2022;36(1):165\u201376. https:\/\/doi.org\/10.1038\/s41375-021-01321-2.","journal-title":"Leukemia"},{"key":"1754_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1228004","author":"Q Zhu","year":"2023","unstructured":"Zhu Q, Yang Y, Deng X, Chao N, Chen Z, Ye Y, et al. High CD8(+)tumor-infiltrating lymphocytes indicate severe exhaustion and poor prognosis in angioimmunoblastic T-cell lymphoma. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1228004.","journal-title":"Front Immunol"},{"key":"1754_CR25","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.66395","author":"S Cheng","year":"2021","unstructured":"Cheng S, Zhang W, Inghirami G, Tam W. Mutation analysis links angioimmunoblastic T-cell lymphoma to clonal hematopoiesis and smoking. Elife. 2021. https:\/\/doi.org\/10.7554\/eLife.66395.","journal-title":"Elife"},{"issue":"15","key":"1754_CR26","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","volume":"133","author":"TB Heavican","year":"2019","unstructured":"Heavican TB, Bouska A, Yu J, Lone W, Amador C, Gong Q, et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood. 2019;133(15):1664\u201376. https:\/\/doi.org\/10.1182\/blood-2018-09-872549.","journal-title":"Blood"},{"issue":"9","key":"1754_CR27","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","volume":"123","author":"O Odejide","year":"2014","unstructured":"Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014;123(9):1293\u20136. https:\/\/doi.org\/10.1182\/blood-2013-10-531509.","journal-title":"Blood"},{"issue":"1","key":"1754_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1746553","volume":"9","author":"GJ Lee","year":"2020","unstructured":"Lee GJ, Jun Y, Yoo HY, Jeon YK, Lee D, Lee S, et al. Angioimmunoblastic T-cell lymphoma-like lymphadenopathy in mice transgenic for human RHOA with p.Gly17Val mutation. Oncoimmunology. 2020;9(1): 1746553. https:\/\/doi.org\/10.1080\/2162402X.2020.1746553.","journal-title":"Oncoimmunology"},{"issue":"7","key":"1754_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.clml.2021.03.002","volume":"21","author":"PN Nguyen","year":"2021","unstructured":"Nguyen PN, Tran N, Nguyen T, Ngo T, Lai DV, Deel CD, et al. Clinicopathological implications of RHOA mutations in angioimmunoblastic T-cell lymphoma: a meta-analysis: RHOA mutations in AITL. Clin Lymphoma Myeloma Leuk. 2021;21(7):431\u20138. https:\/\/doi.org\/10.1016\/j.clml.2021.03.002.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"1754_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ajcp\/aqab090","volume":"156","author":"Y Xie","year":"2021","unstructured":"Xie Y, Jaffe ES. How i diagnose angioimmunoblastic T-cell lymphoma. Am J Clin Pathol. 2021;156(1):1\u201314. https:\/\/doi.org\/10.1093\/ajcp\/aqab090.","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"1754_CR31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/bjh.16428","volume":"189","author":"MA Timmins","year":"2020","unstructured":"Timmins MA, Wagner SD, Ahearne MJ. The new biology of PTCL-NOS and AITL: current status and future clinical impact. Br J Haematol. 2020;189(1):54\u201366. https:\/\/doi.org\/10.1111\/bjh.16428.","journal-title":"Br J Haematol"},{"issue":"9","key":"1754_CR32","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/cup.13475","volume":"46","author":"N Oishi","year":"2019","unstructured":"Oishi N, Sartori-Valinotti JC, Bennani NN, Wada DA, He R, Cappel MA, et al. Cutaneous lesions of angioimmunoblastic T-cell lymphoma: Clinical, pathological, and immunophenotypic features. J Cutan Pathol. 2019;46(9):637\u201344. https:\/\/doi.org\/10.1111\/cup.13475.","journal-title":"J Cutan Pathol"},{"issue":"5","key":"1754_CR33","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2021.04.080","volume":"85","author":"JR Stoll","year":"2021","unstructured":"Stoll JR, Willner J, Oh Y, Pulitzer M, Moskowitz A, Horwitz S, et al. Primary cutaneous T-cell lymphomas other than mycosis fungoides and S\u00e9zary syndrome. Part I: clinical and histologic features and diagnosis. J Am Acad Dermatol. 2021;85(5):1073\u201390. https:\/\/doi.org\/10.1016\/j.jaad.2021.04.080.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1754_CR34","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jaad.2018.08.053","volume":"81","author":"WJ Lee","year":"2019","unstructured":"Lee WJ, Won KH, Choi JW, Won CH, Chang SE, Choi JH, et al. Cutaneous angioimmunoblastic T-cell lymphoma: Epstein-Barr virus positivity and its effects on clinicopathologic features. J Am Acad Dermatol. 2019;81(4):989\u201397. https:\/\/doi.org\/10.1016\/j.jaad.2018.08.053.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1754_CR35","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.12998\/wjcc.v11.i5.1086","volume":"11","author":"M Jiang","year":"2023","unstructured":"Jiang M, Wan JH, Tu Y, Shen Y, Kong FC, Zhang ZL. Angioimmunoblastic T-cell lymphoma induced hemophagocytic lymphohistiocytosis and disseminated intravascular coagulopathy: a case report. World J Clin Cases. 2023;11(5):1086\u201393. https:\/\/doi.org\/10.12998\/wjcc.v11.i5.1086.","journal-title":"World J Clin Cases"},{"issue":"5","key":"1754_CR36","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.anai.2020.01.028","volume":"124","author":"V Eng","year":"2020","unstructured":"Eng V, Kulkarni SK, Kaplan MS, Samant SA, Sheikh J. Hypereosinophilia with angioimmunoblastic T-cell lymphoma. Ann Allergy Asthma Immunol. 2020;124(5):513\u20135. https:\/\/doi.org\/10.1016\/j.anai.2020.01.028.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"1754_CR37","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41375-024-02135-8","volume":"38","author":"J Knauft","year":"2024","unstructured":"Knauft J, Schenk T, Ernst T, Schnetzke U, Hochhaus A, La Ros\u00e9e P, et al. Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis. Leukemia. 2024;38(2):235\u201349. https:\/\/doi.org\/10.1038\/s41375-024-02135-8.","journal-title":"Leukemia"},{"issue":"3","key":"1754_CR38","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/his.15083","volume":"84","author":"E Poullot","year":"2024","unstructured":"Poullot E, Milowich D, Lemonnier F, Bisig B, Robe C, Pelletier L, et al. Angioimmunoblastic T-cell lymphoma and Kaposi sarcoma: a fortuitous collision? Histopathology. 2024;84(3):556\u201364. https:\/\/doi.org\/10.1111\/his.15083.","journal-title":"Histopathology"},{"issue":"4","key":"1754_CR39","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/MOH.0000000000000261","volume":"23","author":"JR Cort\u00e9s","year":"2016","unstructured":"Cort\u00e9s JR, Palomero T. The curious origins of angioimmunoblastic T-cell lymphoma. Curr Opin Hematol. 2016;23(4):434\u201343. https:\/\/doi.org\/10.1097\/MOH.0000000000000261.","journal-title":"Curr Opin Hematol"},{"issue":"18","key":"1754_CR40","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1182\/blood.2020004944","volume":"135","author":"K Liapis","year":"2020","unstructured":"Liapis K, Paterakis G. Circulating angioimmunoblastic T-cell lymphoma cells. Blood. 2020;135(18):1607. https:\/\/doi.org\/10.1182\/blood.2020004944.","journal-title":"Blood"},{"issue":"2","key":"1754_CR41","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1200\/JCO.2012.43.3797","volume":"31","author":"AR Huppmann","year":"2013","unstructured":"Huppmann AR, Roullet MR, Raffeld M, Jaffe ES. Angioimmunoblastic T-cell lymphoma partially obscured by an Epstein-Barr virus-negative clonal plasma cell proliferation. J Clin Oncol. 2013;31(2):e28\u201330. https:\/\/doi.org\/10.1200\/JCO.2012.43.3797.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1754_CR42","doi-asserted-by":"publisher","first-page":"C1121","DOI":"10.1152\/ajpcell.00356.2021","volume":"323","author":"R Henrie","year":"2022","unstructured":"Henrie R, Cherniawsky H, Marcon K, Zhao EJ, Marinkovic A, Pourshahnazari P, et al. Inflammatory diseases in hematology: a review. Am J Physiol Cell Physiol. 2022;323(4):C1121\u201336. https:\/\/doi.org\/10.1152\/ajpcell.00356.2021.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"34","key":"1754_CR43","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016932","volume":"98","author":"P Han","year":"2019","unstructured":"Han P, Yang L, Yan W, Tian D. Angioimmunoblastic T-cell lymphoma mimicking drug fever and infectious etiology after a thyroidectomy: a case report. Medicine. 2019;98(34): e16932. https:\/\/doi.org\/10.1097\/MD.0000000000016932.","journal-title":"Medicine"},{"key":"1754_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1008695","author":"Q Pu","year":"2022","unstructured":"Pu Q, Qiao J, Liu Y, Cao X, Tan R, Yan D, et al. Differential diagnosis and identification of prognostic markers for peripheral T-cell lymphoma subtypes based on flow cytometry immunophenotype profiles. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.1008695.","journal-title":"Front Immunol"},{"issue":"2","key":"1754_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.blre.2015.08.003","volume":"30","author":"J Iqbal","year":"2016","unstructured":"Iqbal J, Wilcox R, Naushad H, Rohr J, Heavican TB, Wang C, et al. Genomic signatures in T-cell lymphoma: how can these improve precision in diagnosis and inform prognosis? Blood Rev. 2016;30(2):89\u2013100. https:\/\/doi.org\/10.1016\/j.blre.2015.08.003.","journal-title":"Blood Rev"},{"issue":"3","key":"1754_CR46","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-020-0301-x","volume":"10","author":"M Yabe","year":"2020","unstructured":"Yabe M, Gao Q, Ozkaya N, Huet S, Lewis N, Pichardo JD, et al. Bright PD-1 expression by flow cytometry is a powerful tool for diagnosis and monitoring of angioimmunoblastic T-cell lymphoma. Blood Cancer J. 2020;10(3):32. https:\/\/doi.org\/10.1038\/s41408-020-0301-x.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1754_CR47","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1038\/s41598-023-33031-3","volume":"13","author":"M Donzel","year":"2023","unstructured":"Donzel M, Trecourt A, Balme B, Harou O, Mauduit C, Bachy E, et al. Deciphering the spectrum of cutaneous lymphomas expressing TFH markers. Sci Rep. 2023;13(1):6500. https:\/\/doi.org\/10.1038\/s41598-023-33031-3.","journal-title":"Sci Rep"},{"issue":"9","key":"1754_CR48","first-page":"11372","volume":"8","author":"W Huang","year":"2015","unstructured":"Huang W, Xie J, Xu X, Gao X, Xie P, Zhou X. MUM-1 expression differentiates AITL with HRS-like cells from cHL. Int J Clin Exp Pathol. 2015;8(9):11372\u20138.","journal-title":"Int J Clin Exp Pathol"},{"issue":"7","key":"1754_CR49","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/ajh.21434","volume":"84","author":"A Carbone","year":"2009","unstructured":"Carbone A, Gloghini A, Cabras A, Elia G. Differentiating germinal center-derived lymphomas through their cellular microenvironment. Am J Hematol. 2009;84(7):435\u20138. https:\/\/doi.org\/10.1002\/ajh.21434.","journal-title":"Am J Hematol"},{"issue":"5","key":"1754_CR50","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1080\/03007995.2024.2337670","volume":"40","author":"X Liang","year":"2024","unstructured":"Liang X, Yang C, Su M, Zou L. Diagnosis of bone marrow involvement in angioimmunoblastic T-cell lymphoma should be based on both [(18)F]FDG-PET\/CT and bone marrow biopsy findings. Curr Med Res Opin. 2024;40(5):803\u201311. https:\/\/doi.org\/10.1080\/03007995.2024.2337670.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"1754_CR51","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1097\/PAS.0000000000001121","volume":"42","author":"JP Balakrishna","year":"2018","unstructured":"Balakrishna JP, Bhavsar T, Nicolae A, Raffeld M, Jaffe ES, Pittaluga S. Human herpes virus 6 (HHV-6)-associated lymphadenitis: pitfalls in diagnosis in benign and malignant settings. Am J Surg Pathol. 2018;42(10):1402\u20138. https:\/\/doi.org\/10.1097\/PAS.0000000000001121.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"1754_CR52","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.critrevonc.2008.06.012","volume":"68","author":"E Iannitto","year":"2008","unstructured":"Iannitto E, Ferreri AJ, Minardi V, Tripodo C, Kreipe HH. Angioimmunoblastic T-cell lymphoma. Crit Rev Oncol Hematol. 2008;68(3):264\u201371. https:\/\/doi.org\/10.1016\/j.critrevonc.2008.06.012.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"1754_CR53","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1080\/10428194.2018.1459610","volume":"59","author":"H Hong","year":"2018","unstructured":"Hong H, Fang X, Wang Z, Huang H, Lam ST, Li F, et al. Angioimmunoblastic T-cell lymphoma: a prognostic model from a retrospective study. Leuk Lymphoma. 2018;59(12):2911\u20136. https:\/\/doi.org\/10.1080\/10428194.2018.1459610.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1754_CR54","doi-asserted-by":"publisher","first-page":"675893094","DOI":"10.1177\/03000605211013274","volume":"49","author":"J Sun","year":"2021","unstructured":"Sun J, He S, Cen H, Zhou D, Li Z, Wang MY, et al. A novel prognostic model for angioimmunoblastic T-cell lymphoma: A retrospective study of 55 cases. J Int Med Res. 2021;49(5):675893094. https:\/\/doi.org\/10.1177\/03000605211013274.","journal-title":"J Int Med Res"},{"issue":"1","key":"1754_CR55","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13550-021-00807-5","volume":"11","author":"H Gong","year":"2021","unstructured":"Gong H, Li T, Li J, Tang L, Ding C. Prognostic value of baseline total metabolic tumour volume of (18)F-FDG PET\/CT imaging in patients with angioimmunoblastic T-cell lymphoma. EJNMMI Res. 2021;11(1):64. https:\/\/doi.org\/10.1186\/s13550-021-00807-5.","journal-title":"EJNMMI Res"},{"key":"1754_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.797028","author":"TY Kim","year":"2021","unstructured":"Kim TY, Min GJ, Jeon YW, Park SS, Park S, Shin SH, et al. Impact of epstein-barr virus on peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.797028.","journal-title":"Front Oncol"},{"issue":"3","key":"1754_CR57","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1053\/j.seminhematol.2023.07.003","volume":"60","author":"YJ Huo","year":"2023","unstructured":"Huo YJ, Zhao WL. Circulating tumor DNA in NK\/T and peripheral T cell lymphoma. Semin Hematol. 2023;60(3):173\u20137. https:\/\/doi.org\/10.1053\/j.seminhematol.2023.07.003.","journal-title":"Semin Hematol"},{"issue":"1","key":"1754_CR58","doi-asserted-by":"publisher","first-page":"291","DOI":"10.4143\/crt.2022.017","volume":"55","author":"SJ Kim","year":"2023","unstructured":"Kim SJ, Kim YJ, Yoon SE, Ryu KJ, Park B, Park D, et al. Circulating tumor DNA-based genotyping and monitoring for predicting disease relapses of patients with peripheral T-cell lymphomas. Cancer Res Treat. 2023;55(1):291\u2013303. https:\/\/doi.org\/10.4143\/crt.2022.017.","journal-title":"Cancer Res Treat"},{"issue":"1","key":"1754_CR59","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-025-01673-7","volume":"18","author":"L Fu","year":"2025","unstructured":"Fu L, Zhou X, Zhang X, Li X, Zhang F, Gu H, et al. Circulating tumor DNA in lymphoma: technologies and applications. J Hematol Oncol. 2025;18(1):29. https:\/\/doi.org\/10.1186\/s13045-025-01673-7.","journal-title":"J Hematol Oncol"},{"issue":"24","key":"1754_CR60","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1182\/bloodadvances.2021005171","volume":"5","author":"M Rodr\u00edguez","year":"2021","unstructured":"Rodr\u00edguez M, Alonso-Alonso R, Tom\u00e1s-Roca L, Rodr\u00edguez-Pinilla SM, Manso-Alonso R, Cereceda L, et al. Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers. Blood Adv. 2021;5(24):5588\u201398. https:\/\/doi.org\/10.1182\/bloodadvances.2021005171.","journal-title":"Blood Adv"},{"issue":"3","key":"1754_CR61","doi-asserted-by":"publisher","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","volume":"20","author":"SM Horwitz","year":"2022","unstructured":"Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, et al. T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(3):285\u2013308. https:\/\/doi.org\/10.6004\/jnccn.2022.0015.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"1754_CR62","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1158\/1078-0432.CCR-22-2955","volume":"29","author":"JC Chavez","year":"2023","unstructured":"Chavez JC, Foss FM, William BM, Brammer JE, Smith SM, Prica A, et al. Targeting the inducible T-cell costimulator (ICOS) in patients with relapsed\/refractory T-follicular helper phenotype peripheral T-cell and angioimmunoblastic T-cell lymphoma. Clin Cancer Res. 2023;29(10):1869\u201378. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2955.","journal-title":"Clin Cancer Res"},{"key":"1754_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.09.008","author":"FO Meeuwes","year":"2022","unstructured":"Meeuwes FO, Brink M, van der Poel M, Kersten MJ, Wondergem M, Mutsaers P, et al. Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis. Eur J Cancer. 2022. https:\/\/doi.org\/10.1016\/j.ejca.2022.09.008.","journal-title":"Eur J Cancer"},{"issue":"18","key":"1754_CR64","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Tr\u00fcmper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418\u201325. https:\/\/doi.org\/10.1182\/blood-2010-02-270785.","journal-title":"Blood"},{"issue":"10","key":"1754_CR65","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstr\u00f6m J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124(10):1570\u20137. https:\/\/doi.org\/10.1182\/blood-2014-04-573089.","journal-title":"Blood"},{"issue":"1","key":"1754_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01560-7","volume":"17","author":"E Chang","year":"2024","unstructured":"Chang E, Tan YH, Chan JY. Novel clinical risk stratification and treatment strategies in relapsed\/refractory peripheral T-cell lymphoma. J Hematol Oncol. 2024;17(1): 38. https:\/\/doi.org\/10.1186\/s13045-024-01560-7.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"1754_CR67","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/annonc\/mdx787","volume":"29","author":"G Fossard","year":"2018","unstructured":"Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018;29(3):715\u201323. https:\/\/doi.org\/10.1093\/annonc\/mdx787.","journal-title":"Ann Oncol"},{"issue":"9","key":"1754_CR68","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/cncr.31861","volume":"125","author":"SI Park","year":"2019","unstructured":"Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019;125(9):1507\u201317. https:\/\/doi.org\/10.1002\/cncr.31861.","journal-title":"Cancer"},{"issue":"2","key":"1754_CR69","doi-asserted-by":"publisher","first-page":"684","DOI":"10.4143\/crt.2022.1434","volume":"55","author":"H Cho","year":"2023","unstructured":"Cho H, Yoon DH, Shin DY, Koh Y, Yoon SS, Kim SJ, et al. Current treatment patterns and the role of upfront autologous stem cell transplantation in patients with peripheral T-cell lymphoma: a Korean nationwide, multicenter prospective registry study (CISL 1404). Cancer Res Treat. 2023;55(2):684\u201392. https:\/\/doi.org\/10.4143\/crt.2022.1434.","journal-title":"Cancer Res Treat"},{"issue":"14","key":"1754_CR70","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1182\/bloodadvances.2023012531","volume":"8","author":"M Brink","year":"2024","unstructured":"Brink M, Huisman F, Meeuwes FO, van der Poel M, Kersten MJ, Wondergem M, et al. Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry. Blood Adv. 2024;8(14):3619\u201328. https:\/\/doi.org\/10.1182\/bloodadvances.2023012531.","journal-title":"Blood Adv"},{"issue":"1","key":"1754_CR71","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s40164-024-00557-9","volume":"13","author":"H Gao","year":"2024","unstructured":"Gao H, Zhang Z, Wang J, Jia Y, Zheng Y, Pei X, et al. Application patterns and outcomes of hematopoietic stem cell transplantation in peripheral T-cell lymphoma patients: a multicenter real-world study in China. Exp Hematol Oncol. 2024;13(1):88. https:\/\/doi.org\/10.1186\/s40164-024-00557-9.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"1754_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03179-5","volume":"43","author":"A Krug","year":"2024","unstructured":"Krug A, Saidane A, Martinello C, Fusil F, Michels A, Buchholz CJ, et al. In vivo CAR T cell therapy against angioimmunoblastic T cell lymphoma. J Exp Clin Cancer Res. 2024;43(1): 262. https:\/\/doi.org\/10.1186\/s13046-024-03179-5.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"1754_CR73","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1038\/s41375-022-01585-2","volume":"36","author":"ML Olson","year":"2022","unstructured":"Olson ML, Mause ERV, Radhakrishnan SV, Brody JD, Rapoport AP, Welm AL, et al. Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion. Leukemia. 2022;36(7):1943\u20136. https:\/\/doi.org\/10.1038\/s41375-022-01585-2.","journal-title":"Leukemia"},{"issue":"26","key":"1754_CR74","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1182\/blood.2021013379","volume":"138","author":"AJ Moskowitz","year":"2021","unstructured":"Moskowitz AJ, Ghione P, Jacobsen E, Ruan J, Schatz JH, Noor S, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas. Blood. 2021;138(26):2828\u201337. https:\/\/doi.org\/10.1182\/blood.2021013379.","journal-title":"Blood"},{"issue":"19","key":"1754_CR75","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.1182\/bloodadvances.2023009767","volume":"7","author":"J Ruan","year":"2023","unstructured":"Ruan J, Zain J, Palmer B, Jovanovic B, Mi X, Swaroop A, et al. Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma. Blood Adv. 2023;7(19):5771\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2023009767.","journal-title":"Blood Adv"},{"issue":"3","key":"1754_CR76","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3324\/haematol.2022.280996","volume":"108","author":"S Rai","year":"2023","unstructured":"Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, et al. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. Haematologica. 2023;108(3):811\u201321. https:\/\/doi.org\/10.3324\/haematol.2022.280996.","journal-title":"Haematologica"},{"issue":"8","key":"1754_CR77","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26(8):1766\u201371. https:\/\/doi.org\/10.1093\/annonc\/mdv237.","journal-title":"Ann Oncol"},{"issue":"1","key":"1754_CR78","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","volume":"10","author":"Y Shi","year":"2017","unstructured":"Shi Y, Jia B, Xu W, Li W, Liu T, Liu P, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol. 2017;10(1):69. https:\/\/doi.org\/10.1186\/s13045-017-0439-6.","journal-title":"J Hematol Oncol"},{"key":"1754_CR79","doi-asserted-by":"publisher","first-page":"6221","DOI":"10.1182\/blood-2023-184830","volume":"142","author":"C Li","year":"2023","unstructured":"Li C, HU H, Lei T, Yu H, Chen X, Peng S, et al. Updated results of a prospective study: rituximab and lenalidomide plus chidamide (RLC) for patients with relapsed\/refractory angioimmunoblastic T-cell lymphoma. Blood. 2023;142:6221. https:\/\/doi.org\/10.1182\/blood-2023-184830.","journal-title":"Blood"},{"issue":"17","key":"1754_CR80","doi-asserted-by":"publisher","first-page":"4903","DOI":"10.1182\/bloodadvances.2022008615","volume":"7","author":"WS Kim","year":"2023","unstructured":"Kim WS, Fukuhara N, Yoon DH, Yamamoto K, Uchida T, Negoro E, et al. Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study. Blood Adv. 2023;7(17):4903\u201312. https:\/\/doi.org\/10.1182\/bloodadvances.2022008615.","journal-title":"Blood Adv"},{"issue":"17","key":"1754_CR81","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1182\/bloodadvances.2024012806","volume":"8","author":"T Witzig","year":"2024","unstructured":"Witzig T, Sokol L, Kim WS, de la Cruz VF, Mart\u00edn GA, Advani R, et al. Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed\/refractory peripheral T-cell lymphoma. Blood Adv. 2024;8(17):4581\u201392. https:\/\/doi.org\/10.1182\/bloodadvances.2024012806.","journal-title":"Blood Adv"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01754-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01754-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01754-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:52:35Z","timestamp":1764917555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01754-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1754"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01754-4","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors declare full consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"218"}}